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Dear Editor
We read with great interest the recently published article by
Esteghamati et al. [1]. In this study, association between
homocysteine (Hcy) and metabolic syndrome (MetS) components
in prediction of coronary heart disease (CHD) was investigated. In
conclusion, serum Hcy level was found to be correlated to MetS
components, especially to systolic blood pressure and the
interaction between Hcy and MetS was claimed as a hazard for
CHD. Moreover, Hcy was determined to potentiate the predictive
value of MetS and traditional risk factors in predicting a CHD event
by reclassifying around 50% of the at-risk population. However, we
would like to share our thoughts and contributions to this study.
First, Hcy, vitamin B12, folic acid, and methylmalonic acid (MMA)
are biomarkers that tend to be associated with each other. Both
MMA and Hcy levels can be the early functional markers for tissue
vitamin B12 deﬁciency, even before hematologic manifestations
occur [2]. However, unlike vitamin B12, nutritional deﬁciency of
folic acid may also lead to abnormal plasma total Hcy accumulation.
Moreover, serum MMA level is more speciﬁc for functional vitamin
B12 deﬁciency than Hcy [3,4]. In the original study, assessing MMA,
vitamin B12 and folic acid levels along with Hcy would provide
more signiﬁcant and speciﬁc results to predict the association
between Hcy and MetS components in prediction of CHD.
Second, as is known, C-peptide measurement is an indicator of
endogenous insulin secretion. Currently, C-peptide results vary
widely among assay methods. C-peptide was measured by
radioimmunoassay (RIA) in the original study. However, in a
study by Rogatsky et al., plasma concentrations of total C-peptide
measured by RIA were consistently higher than by isotope-dilution
assay liquid chromatography–mass spectrometry (IDA LC/MS),
consistent with the higher speciﬁcity of IDAs compared with
immunoassays [5]. It would therefore be more appropriate to
measure C-peptide levels by MS-based techniques.
Third, in statistical analysis, authors have used the parameters
and tests such as mean  standard deviation (SD) and ANOVA that
are valid for Gaussian distribution. However, as can be seen in
Table 1 in the original study, SD values of fasting plasma glucose,
insulin, homeostatic model assessment of insulin resistance, and
triglyceride are so close to their mean values. This circumstance is
usually seen when data are skewed. Therefore, Kolmogorov–Smirnov
test should be performed to test whether there is a normal (known as
Gaussian) distribution at the onset of the statistical analysis. The
parameter that shows Gaussian distribution should be expressed as
mean  SD and if data are skewed, values should be presented as
median (25th–75th interquartile range). According to the results
ANOVA or Kruskal–Wallis variance analysis should be performed for0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsmultigroup comparisons. Therefore, this situation may cause
misinterpretation of results as well as false binary comparisons. In
other words, an insigniﬁcant p-value will perhaps be signiﬁcant or
vice versa.
In conclusion, assessment of the Hcy interfering parameters
together with use of proper diagnostic tools and statistical analysis
are important to get reliable results.
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